The mechanism of action of teprotumumab in patients with TED has not been fully characterized. Teprotumumab-trbw binds to IGF-1R and blocks its activation and signaling.

IGF-1R, insulin-like growth factor-1 receptor.

Helpful resources and downloadable assets to support your practice and your patients

Patient Enrollment Form

Download the form, complete it with your patient, including HCP and patient signatures, and submit by fax or email.

COMPLETE THE PDF

DocuSign® eSignature Patient Enrollment Form

Complete the form and send to your patient via email to sign electronically via DocuSign®.

DOCUSIGN®

Treatment initiation resources

A guide on how to complete the TEPEZZA patient enrollment form to begin the treatment process.

DOWNLOAD

Helpful information to consider when selecting a site of care for your patient’s TEPEZZA infusion.

DOWNLOAD

A customizable letter used to notify co-managers and coordinate patient monitoring when TEPEZZA is initiated.

DOWNLOAD

Information on how to co-manage patients throughout the course of treatment.

DOWNLOAD

Answers to common questions about home infusion for TEPEZZA.

DOWNLOAD

Considerations for choosing home infusion for TEPEZZA.

DOWNLOAD

Payor access resources

A guide to documenting TED symptomatology with a focus on capturing key clinical criteria such as Clinical Activity Score (CAS).

DOWNLOAD

This form outlines the CAS that is used to evaluate the inflammatory signs and symptoms of TED.

DOWNLOAD

A customizable letter of medical necessity template to support PA for TEPEZZA.

DOWNLOAD

A customizable appeals template for patient cases that were denied PA.

DOWNLOAD

PA, prior authorization.

Billing and coding resources

A guide to TEPEZZA specialty distributors, specialty pharmacies, and ordering.

DOWNLOAD

Product information, including NDC, packaging, storage, handling, and authorized distributor list.

DOWNLOAD

A guide to billing procedures, necessary codes, and reimbursement with J-code.

DOWNLOAD

A guide to necessary codes for billing and reimbursement with J-code.

DOWNLOAD

Infusion resources

A step-by-step checklist for the infusion process.

DOWNLOAD

A detailed guide to preparing, administering, and infusing TEPEZZA.

DOWNLOAD

Icon of Infusion administration video

Key steps required for reconstitution, dilution, and administration of TEPEZZA.

Watch Video

Patient education resources

A brochure to guide your patients through the initial steps of getting started on TEPEZZA.

DOWNLOAD

Icon of Getting started on TEPEZZA video

A video to help your patients understand how to get started on TEPEZZA.

Watch Video

A brochure to guide your patients through insurance coverage and approval of TEPEZZA.

DOWNLOAD

A list that helps your patients prepare for TEPEZZA infusions.

DOWNLOAD

A list that helps your patients stay on track after each TEPEZZA infusion.

DOWNLOAD

logoFor additional resources for your practice,
please visit Horizon By Your Side.

logoFor additional resources for your patients,
please visit the TEPEZZA patient website.

INDICATION

TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.

Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA.

Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be controlled with medications for glycemic control, if necessary. Assess patients for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment with TEPEZZA. Ensure patients with hyperglycemia or preexisting diabetes are under appropriate glycemic control before and while receiving TEPEZZA.

Hearing Impairment Including Hearing Loss: TEPEZZA may cause severe hearing impairment including hearing loss, which in some cases may be permanent. Assess patients’ hearing before, during, and after treatment with TEPEZZA and consider the benefit-risk of treatment with patients.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, dry skin, weight decreased, nail disorders, and menstrual disorders.

Please see Full Prescribing Information for more information.

INDICATION

TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.

Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA.

Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be controlled with medications for glycemic control, if necessary. Assess patients for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment with TEPEZZA. Ensure patients with hyperglycemia or preexisting diabetes are under appropriate glycemic control before and while receiving TEPEZZA.

Hearing Impairment Including Hearing Loss: TEPEZZA may cause severe hearing impairment including hearing loss, which in some cases may be permanent. Assess patients’ hearing before, during, and after treatment with TEPEZZA and consider the benefit-risk of treatment with patients.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, dry skin, weight decreased, nail disorders, and menstrual disorders.

Please see Full Prescribing Information for more information.